Celltrion Pharm Stock Current Valuation
| 068760 Stock | KRW 56,900 700.00 1.22% |
Valuation analysis of Celltrion Pharm helps investors to measure Celltrion Pharm's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Celltrion Pharm's price fluctuation is very steady at this time. Calculation of the real value of Celltrion Pharm is based on 3 months time horizon. Increasing Celltrion Pharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Celltrion Pharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Celltrion Stock. However, Celltrion Pharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 56900.0 | Real 47198.0 | Hype 56900.0 | Naive 54317.6 |
The real value of Celltrion Stock, also known as its intrinsic value, is the underlying worth of Celltrion Pharm Company, which is reflected in its stock price. It is based on Celltrion Pharm's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Celltrion Pharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Celltrion Pharm helps investors to forecast how Celltrion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Celltrion Pharm more accurately as focusing exclusively on Celltrion Pharm's fundamentals will not take into account other important factors: Celltrion Pharm Company Current Valuation Analysis
Celltrion Pharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Celltrion Pharm Current Valuation | 5.87 T |
Most of Celltrion Pharm's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celltrion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Celltrion Pharm has a Current Valuation of 5.87 T. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
Celltrion Pharm is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 11.73 Trillion. Celltrion Pharm totals roughly 5.87 Trillion in current valuation claiming about 50% of equities under Health Care industry.Celltrion Fundamentals
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 34.05 M | |||
| Shares Owned By Insiders | 57.79 % | |||
| Shares Owned By Institutions | 6.75 % | |||
| Price To Earning | 62.82 X | |||
| Price To Sales | 8.22 X | |||
| Revenue | 398.74 B | |||
| Gross Profit | 72.93 B | |||
| EBITDA | 42.8 B | |||
| Net Income | 34.58 B | |||
| Cash And Equivalents | 80.19 B | |||
| Cash Per Share | 815.33 X | |||
| Total Debt | 39.4 B | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.25 X | |||
| Book Value Per Share | 10,914 X | |||
| Cash Flow From Operations | 93.15 B | |||
| Target Price | 136000.0 | |||
| Number Of Employees | 29 | |||
| Beta | 0.23 | |||
| Market Capitalization | 2.1 T | |||
| Total Asset | 637.88 B | |||
| Retained Earnings | 30.6 B | |||
| Working Capital | 58.94 B | |||
| Current Asset | 144.21 B | |||
| Current Liabilities | 85.27 B | |||
| Z Score | 31.8 | |||
| Net Asset | 637.88 B |
About Celltrion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.